#Ozempic

Novo Nordisk and Hims & Hers have ended their legal battle with a partnership that could reshape the booming compounded GLP-1 drug market and limit cheaper alternatives.

With one in eight American adults now taking GLP-1 medications like Ozempic and Wegovy, researchers at Georgia State University have uncovered why patients regain weight after stopping treatment — and a potential combination therapy that could solve the problem by targeting the brain's stress response system.